In patients with critical illness and NSTEMI, it can be difficult to distinguish demand-ischemia from an underlying plaque rupture, especially in patients with CKD or without CAD risk factors or prior coronary angiography. Troponin is usually trended but the rise may be gradual/plateaus. A TTE is useful for looking for signs of infarct, but it may be delayed in order to optimize fluid-status as a possible source of demand-ischemia. The delay may lead to a missed event.
In patients with acute illness (sepsis, volume overload, pneumonia), what pushes you to consider a Type 1 over a Type 2 NSTEMI? Are there biomarkers under development that are more specific for plaque rupture to differentiate a Type 1 from a Type 2 NSTEMI?
Easy one-click social registrationIs this safe?
We only receive the minimum information necessary to verify your account. We never get access to your friends/contacts or your profile, and we never post on your behalf. Your social account is used for logging in only.ORRegister via email
Send me updates on this Contest
In order to ensure a fair voting process and to make sure that no one votes more than once, we ask that you register either with a social networking account (easiest, only requires one click) or by registering with your email address (this will require you to click on a verification email that we will send you).
You only need to register once.